ZNT has got to be the cheapest roll up play in the market right now. FY18 guidance is for $13.5M EBITDA and the recent acquisitions should add a further run rate of circa $2.5M EBITDA. That's a total of $16M run rate EBITDA. The company should deploy a further $20M or more from the recent cap raise at around 5x which should add another $4M EBITDA before the end of FY18. Therefore as a base case start for FY19 we should have a diversified national healthcare services company with $20M EBITDA and growing organically at 5-10% pa. The current market cap is $94M. I estimate NPAT run rate based on FY19 assumptions above to be circa $11M. That's an EPS of 15 cents. The stock should trade on at least 15x PE multiple. Therefore ZNT is worth at least $2.25 next year. With only 2 brokers covering the stock it is still very much under the radar......
- Forums
- ASX - By Stock
- ZNT
- The most undervalued roll-up stock on the ASX
The most undervalued roll-up stock on the ASX
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ZNT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online